Daiichi Sankyo Absorbs 130 Medical Representatives From Merck KGaA
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo announced July 16 that its German subsidiary agreed to take in 130 medical representatives from Merck KGaA. Since Merck KGaA's decision not to continue marketing activities to medical facilities for drugs whose patents have expired, Daiichi Sankyo decided to take half of the medical representatives and merge them into its own sales force. Currently, 70 percent of Daiichi Sankyo's sales come from the Japanese domestic market. The company hopes to reach 70 percent of sales from the overseas market by 2015. The company is rapidly expanding business in Europe, and in Germany, it has acquired bio-pharmaceutical company Morphosys and antibody maker U3 Pharma. (Click here for more - Japanese language) "In Germany Daiichi Sankyo Takes In 130 Medical Representatives From Merck" - NNA News (7/18/08)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.